Abstract
Eph receptor tyrosine kinases and their cell-surfacebound ligands, the ephrins, play key roles in diverse biological processes. Eph receptors comprise the largest family of receptor tyrosine kinases consisting of eight EphA receptors (with five corresponding ephrinA ligands) and six EphB receptors (with three corresponding transmembrane ephrinB ligands). Originally identified as neuronal pathfinding molecules, EphB receptors and ephrinB ligands are later proved to be crucial regulators of vasculogenesis and embryogenesis. More studies indicate that Eph receptors are involved in angiogenesis and tumorigenesis. This study aimed to investigate the expression of EphB2 and EphB4 in breast carcinomas. Semiquantitative RT-PCR and immunohistochemistry were used to examine the expression patterns of EphB2 and EphB4. Clinicopathological and survival correlations were statistically analyzed in a series of 94 breast carcinomas, 9 normal specimens and 4 breast carcinoma cell lines. 1(1%), 16(17%), 29(31%), 48(51%) of the 94 tumors were negative, weak, moderate and strong EphB2 protein expression, respectively. 6(6%), 27(29%), 28(30%), 33(35%) of the tumors were negative, weak, moderate and strong EphB4 expression, respectively. Both EphB2 and EphB4 RT-PCR products could be detected in all specimens. Increased EphB2 protein expression was negatively associated with overall survival, and there was a trend that increased EphB2 protein expression was correlated with shorter disease free survival, while EphB4 protein expression was associated with histological grade and stage. EphB4 membrane staining was increased with S phase fraction and associated with DNA aneuploidy. These findings indicate that both EphB2 and EphB4 are involved in the development of breast cancer and that both molecules could be potential predictive markers.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Ann Rev Cell Biol 10: 251–337, 1994.
Gale N., Holland SJ., Valenzuela DM, et al: Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17: 9–19, 1996.
Davy A, Gale NW, Murray EW, et al: Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev 13: 3125–3135, 1999.
Davy A., Robbins SM: Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner. Embo J 19: 5396–5405, 2000.
Kullander K, Klein R: Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3: 475–486, 2002.
Flanagan JG, Vanderhaeghen P: The ephrins and Eph receptors in neural development. Ann Rev Neurosci 21: 309–345, 1998.
Tessier-Lavigne M: Eph receptor tyrosine kinases, axon repulsion, and the development of topographic maps. Cell 82: 345–348, 1995.
Wang HU, Anderson DJ: Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth. Neuron 18: 383–396, 1997.
Winslow JW, Moran P, Valverde J, et al: Cloning of AL-1, alig- and for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron 14: 973–981, 1995.
Chinoy MR, Graybill MM, Miller SA, et al: Angiopoietin-1 and VEGF in vascular development and angiogenesis in hypoplastic lungs. Am J Physiol Lung Cell Mol Physiol 283: L60–66, 2002.
Li H, Fredriksson L, Li X, et al: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 22: 1501–1510, 2003.
Goede V., Fleckenstein G, Dietrich M, et al: Prognostic value of angiogenesis in mammary tumors. Anticancer Res 18: 2199–2210, 1998.
Kuehn R, Lelkes PI, Bloechle C, et al: Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 18: 96–103, 1999.
Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst 84: 1875–1882, 1992.
Zelinski DP, Zantek ND, Stewart JC, et al: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301–2311, 2001.
Miyazaki T, Kato H, Fukuchi M, et al: EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103: 657–668, 2003.
Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41: 275–281, 1999.
Ikegaki N, Tang XX, Liu XG, et al: Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyro sine kinase gene of the EPH family. Hum Mol Genet 4: 2033–2041, 1995.
Nikolova Z, Djonov V, Zuercher G, et al: Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci 111: 2741–2750, 1998.
Cromer A, Carles A, Millon R, et al: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene (in press), 2004.
Kiyokawa E, Takai S, Tanaka M, et al: Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 54: 3645–3652, 1994.
Tang XX, Brodeur GM, Campling BG, et al: Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res 5: 455–463, 1999.
Tang XX, Evans AE, Zhao H, et al: High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 5: 1491–1501, 1999.
Tang XX, Evan, AE, Zhao H, et al: Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 36: 80–86, 2001.
Liu W, Ahmad SA, Jung YD, et al: Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94: 934–943, 2002.
Kataoka H, Tanaka M, Kanamori M, et al: Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 128: 343–352, 2002.
Bennett BD, Wang Z, Kuang WJ, et al: Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem 269: 14211–14220, 1994.
Bercla G, Karamitopoulou E, Mazzucchelli L, et al: Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 14: 220–227, 2003.
Stephenson SA, Slomka S, Douglas EL, et al: Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2: 15–21, 2001.
Berclaz G, Flutsch B, Altermatt HJ, et al: Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 9: 985–993, 2002.
Elston CW, Elli, IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–411, 1991.
Suo Z, Berner HS, Risberg B, et al: Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 439: 62–73, 2001.
Himanen JP, Rajashankar KR, Lackmann M, et al: Crystal structure of an Eph receptor-ephrin complex. Nature 414: 933–939, 2001.
Kalo MS, Pasquale EB: Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry 38: 14396–14401, 1999.
Dodelet VC, Pazzagli C, Zisch AH, et al: A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rapl A. J Biol Chem 274: 31941–31946, 1999.
Holland SJ, Gale NW, Gish GD, et al: Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. Embo J 16: 3877–3884, 1997.
Ellis C, Kasmi F, Ganju P, et al: A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. Oncogene 12: 1727–1733, 1996.
Steinte JJ, Meininger CJ, Forough R, et al: Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 277: 43830–43836, 2002.
Vindis C, Cerretti DP, Daniel TO, et al: EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis. J Cell Biol 162: 661–669, 2003.
Stein E, Cerretti DP, Daniel TO: Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells. J Biol Chem 271: 23588–23596, 1996.
Stein E, Huynh-Do U, Lane AA, et al: Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem 273: 1303–1312, 1998.
Hock B, Bohme B, Karn T, et al: PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc Natl Acad Sci U S A 95: 9779–9785, 1998.
Stein E, Lane AA, Cerretti DP, et al: Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 12: 667–672, 1998.
Wybenga-Groot LE, Baskin B, Ong SH, et al: Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745–753, 2001.
Matsuzaki M, Nagase S, Abe T, et al: Detailed deletion mapping on chromosome 1p32–p36 in human colorectal cancer: identification of three distinct regions of common allelic loss. Int J Oncol 13: 1229–1238, 1998.
Praml C, Finke LH, Herfarth C, et al: Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 11: 1357–1367, 1995.
Oba SM, Wang YJ, Song JP, et al: Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer. Cancer Lett 164:97–109, 2001.
Adams RH: Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 13: 55–63, 2002.
Wang HU, Chen ZF, Anderson DJ: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741–753, 1998.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, Q., Suo, Z., Risberg, B. et al. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol. Oncol. Res. 10, 26–33 (2004). https://doi.org/10.1007/BF02893405
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893405